TRIPLE NEGATIVE BREAST CANCER

This is the first study in people testing a new drug called CTX-8371 for several advanced cancers that have stopped responding to standard treatments. Researchers will give increasing doses to a small group of patients to check if the drug is safe and what side effects it causes.…

This study is testing if a short, one-week course of two drugs (lenvatinib and pembrolizumab) given before surgery can help the patient's own immune system fight early-stage triple-negative breast cancer. It will enroll about 12 participants who have not yet had any cancer treatm…

This study is comparing two different chemotherapy combinations for women with advanced triple-negative breast cancer, a particularly aggressive form of the disease. Researchers want to see which combination works better at controlling cancer growth and has fewer side effects. Th…

This study is testing whether combining three drugs—atezolizumab, vinorelbine, and cyclophosphamide—can help control advanced triple-negative breast cancer in patients who have already received immunotherapy. The trial aims to see if this combination can shrink tumors and extend …

This early-stage trial tests whether a patient's own immune cells can be genetically modified to recognize and attack their cancer. The study is for adults with advanced cancers that have spread and express a specific marker called NY-ESO-1. Researchers will first find the safest…

This study is testing two different dosing schedules of a three-drug combination (chemotherapy plus an immunotherapy drug) given before surgery for early triple-negative breast cancer. The goal is to see which schedule is more effective at completely eliminating cancer from the b…

This study is testing a combination of three treatments—an immunotherapy drug (atezolizumab), a new immune-stimulating drug (BDB001), and targeted radiation—to see if they can better control advanced solid tumors. It is enrolling 247 adults with specific advanced cancers, includi…

This study is testing whether a personalized nutrition and exercise program can help chemotherapy work better for women with a specific type of breast cancer. About 160 women receiving chemotherapy before surgery will be randomly assigned to either follow the new lifestyle progra…

This early-stage study aims to find a safe and effective dose of a new drug called AZD6750, which is designed to boost the immune system to fight cancer. It will test the drug alone and combined with other cancer treatments in about 60 adults with advanced or spreading solid tumo…

This study is testing if adding the antibiotic moxifloxacin to standard first-line chemotherapy helps people with metastatic triple-negative breast cancer live longer without their cancer getting worse. It will involve about 228 participants across multiple centers. Patients will…

This early-stage study is testing a new oral medication called PF-08032562, both alone and in combination with other cancer drugs, for people with advanced or metastatic breast or colorectal cancer. The main goals are to find a safe dose and see how the body processes the drug. R…

This early-stage trial is testing a personalized vaccine called NECVAX-NEO1. It is given alongside standard chemotherapy and immunotherapy to patients with triple-negative breast cancer before surgery. The goal is to see if adding this custom-made vaccine, designed to target each…

This study is testing whether a new two-drug immunotherapy combination can shrink tumors in patients with stage II or III triple-negative breast cancer before they start standard chemotherapy. The trial will enroll 12 patients who have not yet received any treatment for their can…

This is the first human trial of a new experimental cancer drug called LY4175408. It is designed to target and deliver a toxic payload specifically to cancer cells that have a certain marker (PTK7). The study will test the drug's safety, side effects, and early signs of effective…

This study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…

This is the first study in people to test a new oral drug called ATX-295, which works by blocking a specific protein that helps cancer cells divide. The main goals are to find a safe dose and see how the body processes the drug in about 90 patients with advanced solid tumors, inc…

This is the first study in people to test a new oral medication called CID-078 for advanced solid tumors. The main goals are to find a safe dose and see how well the body handles the drug. The study will enroll adults with cancers like triple-negative breast cancer, small cell lu…

This study is testing whether adding a targeted drug (sacituzumab govitecan) and an immunotherapy drug (zimberelimab) to precise brain radiation works better and is safe for people with triple negative breast cancer that has spread to the brain. It will involve about 31 participa…

This study is testing a different dose and schedule for the drug sacituzumab govitecan in people with advanced triple-negative breast cancer. The main goals are to see if this new schedule is safe and if it helps shrink tumors or delay cancer growth. The study will enroll about 1…

This study is testing a personalized approach to treat stage 2 or 3 triple negative breast cancer before surgery. It aims to see if an early PET scan after one treatment cycle can predict if the cancer is responding, allowing doctors to adjust the treatment plan. The goal is to m…

This study aims to personalize treatment for triple-negative breast cancer before surgery. It will test if the number of immune cells in a patient's tumor and how well the tumor shrinks on MRI scans can help doctors decide the best type and amount of chemo-immunotherapy. The goal…

This study is testing whether giving vitamin D supplements to patients with triple-negative breast cancer who are also vitamin D deficient can help their chemotherapy work better. Researchers want to see if the supplements help more patients achieve a 'pathologic complete respons…

This large Phase 3 trial is testing whether a new two-drug combination works better than current standard treatments to prevent cancer from coming back in people with triple-negative breast cancer. The study is for patients who had chemotherapy before surgery but still had some c…

This study is testing a new drug called LBL-024, given alone or with a standard chemotherapy drug, for people with advanced triple-negative breast cancer that has returned or spread. The main goals are to see if the treatment is safe and if it can shrink tumors or slow the cancer…

This early-stage study is testing a new radioactive drug treatment for people with advanced solid tumors that have stopped responding to standard therapies. Researchers will first use a special imaging scan to see if patients' tumors are likely to respond, then give the radioacti…

This study is testing whether a new two-drug combination given after surgery works better and is safer than standard treatments for people with triple-negative breast cancer that didn't fully disappear with initial therapy. It will involve about 1,500 participants who still have …

This study is for people with early-stage triple-negative breast cancer, a type known for being aggressive. It compares two drug combinations given before surgery to see if they can effectively eliminate the cancer while being easier to tolerate than standard chemotherapy. The tr…

This study is testing whether adding an immunotherapy drug (pembrolizumab) to a targeted chemotherapy drug (sacituzumab govitecan) works better than the chemotherapy drug alone. It is for people with a specific, hard-to-treat type of advanced breast cancer (triple-negative and PD…

This study aims to see how well a specific chemotherapy combination works for Nigerian women with triple-negative breast cancer, a particularly aggressive form. Researchers will measure how many women have no detectable cancer after treatment and will also look for signals in the…

This is an early-stage study to find a safe dose and see if a new drug combination can help the immune system fight advanced cancers. It will test the experimental drug ASTX660 together with the immunotherapy pembrolizumab in up to 61 adults with solid tumors that have stopped re…

This study is testing several different combinations of drugs to see if they can help immunotherapy work again for people with advanced triple-negative breast cancer whose cancer got worse during previous immunotherapy. It will enroll about 80 patients whose cancer has spread and…

This is the first study in people to test a new oral drug called NKT3964. It aims to see if the drug is safe and can help control advanced cancers that have spread and stopped responding to standard treatments. The study will enroll adults with specific advanced solid tumors, inc…

This is an early-stage study to test a new oral medication called VLS-1488 in adults with advanced solid tumors. The main goals are to find a safe dose and see if the drug shows any early signs of helping to control the cancer. The study is for people with specific advanced cance…

This study is testing whether a new drug called SKB264 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has spread or returned and cannot be removed by surgery. It will involve 524 patients who have not yet received treatment for…

This early-stage study is testing a new drug called APL-5125 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink tumors, especially in colorectal canc…

This is a first-in-human study to find a safe and effective dose of a new drug called ONM-501. The drug is injected directly into tumors and is being tested alone and in combination with an approved immunotherapy drug (cemiplimab) in adults with advanced cancers that have stopped…

This is the first study in people to test the safety and behavior of a new drug called azirkitug. It will be given alone and in combination with two other cancer drugs to adults with advanced solid tumors, including lung and head and neck cancers, who have already tried standard …

This study is testing whether the drug sacituzumab govitecan, alone or combined with pembrolizumab, can shrink tumors before surgery in people with localized triple-negative breast cancer. About 260 participants will receive the study treatment for up to 12 weeks, followed by sta…

This early-stage study is testing a new type of personalized vaccine, made from a patient's own immune cells, given directly into the tumor along with standard chemotherapy. It aims to see if this combination is safe and can help shrink tumors in people with aggressive forms of b…

This study is for women with a specific, hard-to-treat type of triple-negative breast cancer who have already had surgery. It aims to see if adding a drug called 'antivascular therapy' to standard chemotherapy is better at preventing the cancer from returning than chemotherapy al…

This study is testing whether adding a copper-lowering drug called tetrathiomolybdate (TM) to standard post-surgery medications can better prevent cancer from spreading or returning in people with high-risk triple-negative breast cancer. It will involve about 204 participants who…

This study is testing whether a combination of three drugs (pembrolizumab, carboplatin, and paclitaxel) can effectively shrink early-stage triple-negative breast cancer tumors before surgery. The goal is to see if this approach can help patients avoid more intensive chemotherapy …

This study is testing whether genetic information from a patient's tumor can help doctors personalize radiation doses after breast cancer surgery. Researchers want to see if this approach improves cancer control while maintaining quality of life. The trial includes 86 people with…

This trial is testing a new treatment combination for an aggressive type of breast cancer (triple-negative) in patients who have heart problems and cannot safely receive the usual chemotherapy drugs. The goal is to see if a 12-18 week regimen of three different drugs (carboplatin…

This is the first study in people to test a new drug called BL-B01D1. It aims to find a safe dose and see if it can help control advanced cancers that have spread or cannot be removed by surgery. The trial will enroll about 470 adults with various solid tumors, including lung, br…

This is a first-in-human study to test the safety and find the right dose of a new investigational drug called LY4052031 for people with advanced or metastatic solid tumors. The drug is designed to target a specific protein found on many cancer cells, delivering its medicine dire…

This study is testing which of two chemotherapy combinations works better to shrink tumors before surgery for triple-negative breast cancer, an aggressive type. Researchers will compare nab-paclitaxel with carboplatin versus nab-paclitaxel with epirubicin in 520 women. The goal i…

This study is testing a new type of cell therapy called A2B395 for adults with advanced solid tumors that have spread or returned. The therapy uses modified immune cells designed to specifically kill cancer cells while protecting the patient's healthy cells. The main goals are to…

This early-stage trial is testing a personalized vaccine for people with high-risk triple-negative breast cancer who still have cancer cells after standard chemotherapy and surgery. Doctors create a custom vaccine from the patient's own tumor and immune cells, aiming to train the…

This early-stage study is testing the safety of a new type of treatment called CAR-T cell therapy for adults with triple negative breast cancer that has returned or stopped responding to other treatments. Doctors will collect a patient's own immune cells, modify them in a lab to …

This early-stage study is testing a new cancer vaccine called Modi-1. The goal is to see if it is safe and can help the body's immune system fight advanced forms of breast, head and neck, ovarian, and kidney cancer. Researchers will give the vaccine alone or combined with other a…

This is the first human study of an experimental cancer drug called LY4101174. Researchers want to find a safe dose and see if it can help control advanced cancers that have spread or returned after other treatments. The study will enroll about 490 people with various solid tumor…

This is the first study in people to test a new drug called XMT-1660 for several types of advanced solid tumors that have returned or spread. The main goals are to find a safe dose and see what side effects it causes. Researchers will also look for early signs that the drug can s…

This is a first-in-human safety study testing a new immune-boosting vaccine for breast cancer that has spread to the membranes surrounding the brain and spinal cord. Researchers will give the vaccine directly into the spinal fluid of up to 18 patients to find the highest dose tha…

This study is for people with advanced triple-negative breast cancer whose disease is stable or shrinking after initial treatment. It aims to see if continuing immunotherapy with longer time between doses works as well as the standard schedule at keeping the cancer under control.…

This early-stage study is testing a new drug called bulumtatug fuvedotin for people with advanced triple-negative breast cancer that has returned or spread. The trial is for patients who have already tried other targeted treatments called antibody-drug conjugates. Researchers wan…

This study is testing a new drug called Rina-S in people whose solid tumor cancers have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug can shrink tumors. It is for people with several types of advanced cancer, including ovarian,…

This study is testing if a two-drug combination works better than a single drug for people with a specific, hard-to-treat type of advanced breast cancer that has spread. It will involve about 140 adults with a form of breast cancer that doesn't respond to standard hormone or targ…

This is the first human study of an experimental drug called JANX008 for people with advanced solid tumors that have spread and stopped responding to standard treatments. The main goal is to find a safe dose and understand how the body handles the drug. Researchers will also look…

This study is testing a personalized treatment plan for early-stage triple-negative breast cancer. It aims to see if patients whose tumors have high levels of certain immune cells can safely avoid or receive less chemotherapy after surgery. The goal is to control the cancer while…

This study is testing a new targeted drug, VEGFR BP102, combined with standard chemotherapy, against standard chemotherapy alone. It is for people with a specific, aggressive form of advanced triple-negative breast cancer (called the BLIS subtype) that has spread or cannot be sur…

This study is testing whether using a highly focused, high-dose radiation treatment on all visible tumor sites can help people with a limited number of cancer metastases live longer without their disease getting worse. It is for adults with breast cancer or non-small cell lung ca…

This early-stage study is testing a new radioactive drug called [177Lu]Lu-NNS309 in patients with advanced pancreatic, lung, breast, or colorectal cancers that have stopped responding to standard treatments. Researchers will first use a special imaging scan to see if patients' tu…

This is an early-stage study to check the safety and initial activity of an experimental drug called DR-0202. It is for adults with advanced cancers that have spread, returned, or stopped responding to at least two prior treatments. The main goal is to find a safe dose and see ho…

This study is testing whether adding immunotherapy drugs (pembrolizumab with or without olaparib) to standard radiation therapy is safe and more effective at controlling metastatic breast cancer than radiation alone. It is for adults with specific types of breast cancer (triple-n…

This study is testing if adding the drug tocilizumab to standard chemotherapy works better than chemotherapy alone for controlling metastatic triple-negative or estrogen-receptor-low breast cancer. It will enroll 168 Black and non-Black patients to see if the combination improves…

This study is testing two different drug combinations as first treatment for advanced triple-negative breast cancer that has returned or spread. Researchers want to see if adding the experimental drug JS207 to either 9MW2821 or albumin paclitaxel helps control the cancer better. …

This early-stage study is testing the safety and effectiveness of combining two drugs, palbociclib and avelumab, for patients with advanced breast cancer. It focuses on a specific, hard-to-treat type called AR-positive triple-negative breast cancer. The goal is to see if this new…

This study is testing whether a new monitoring approach can find returning triple negative breast cancer earlier. It will track 450 women at high risk of their cancer coming back using regular blood tests that look for tiny pieces of tumor DNA. If the blood test turns positive, h…

This study is testing whether a special full-body MRI scan can find breast cancer that has returned or spread to other parts of the body earlier than current methods. It will enroll 145 women with high-risk forms of breast cancer (HER2-positive or Triple Negative) who have finish…

This study is testing whether regular MRI brain scans can help find breast cancer that has spread to the brain earlier than usual. It involves patients with certain aggressive or metastatic breast cancer types where brain screening is not currently standard. The goal is to see if…

This study is testing if a special type of mammogram that uses a contrast dye can work as well as a breast MRI to see if chemotherapy successfully shrank a breast tumor before surgery. It involves about 30 people with locally advanced breast cancer who are getting chemotherapy be…

This study aims to learn if a blood test that looks for tiny pieces of tumor DNA can predict how well chemotherapy works for breast cancer patients. It will observe 125 women with stage II or III breast cancer who are receiving chemotherapy before surgery. Researchers will track …

This study aims to find the best combination of imaging scans to predict if a patient's triple-negative breast cancer will completely disappear after receiving chemotherapy and immunotherapy before surgery. Researchers will compare results from four different types of scans (ultr…

This study aims to collect tumor samples from people with triple-negative breast cancer to grow them into 3D models called organoids in the lab. Researchers will use these 'mini-tumors' to test how well new, innovative therapies might work and to search for biological markers tha…

This study aims to find out if regular brain MRI scans can detect cancer that has spread to the brain in patients with advanced breast cancer who have no neurological symptoms. Researchers will enroll 170 patients with stage IV breast cancer to see how often these scans find hidd…

This study aims to understand how a breast cancer treatment that nearly eliminates estrogen affects the heart. Researchers will compare heart function in 90 premenopausal women receiving this therapy to those receiving other treatments, using heart scans over two years. The goal …

This study aims to collect and store tumor tissue and blood samples from patients with certain cancers. The goal is to better understand the relationship between a tumor's genetic makeup, its surrounding environment, and the body's immune response. Patients will receive standard …

This study aims to understand how breast cancer changes and becomes resistant to treatment by taking multiple tissue samples from different tumor sites over time. Researchers will collect biopsy samples from 200 people with metastatic breast cancer at diagnosis and when their can…

This study is testing if a new type of PET scan can predict how well a patient's triple-negative breast cancer will respond to a standard combination of chemotherapy and immunotherapy before they even start treatment. Researchers will scan 60 patients with early-stage, high-risk …

This study is testing whether a special type of PET/MRI scan can help doctors see how well immunotherapy is working for patients with triple negative breast cancer. It will enroll 20 patients who are already scheduled to receive immunotherapy. The scans are for research only and …